Predictors of slow responsiveness and partial mucosal recovery in adult patients with celiac disease
Gastroenterology and Hepatology from Bed to Bench,
Vol. 16 No. 2 (2023),
21 April 2023
https://doi.org/10.22037/ghfbb.v16i2.2734
Abstract
Aim: The present study aims to determine the rate of mucosal recovery and predictors of persistent mucosal damage after gluten free diet (GFD).
Background: Celiac disease (CD) is a complex multi-systemic autoimmune disease triggered by exposure to dietary gluten in genetically predisposed individuals. There is still little evidence on the best method for assessing GFD adherence and mucosal recovery during treatment.
Methods: The retrospective study included only adult patients (age≥18 years old), with biopsy-proven CD evaluated at a tertiary referral centre between 2016-2021. We performed a logistic regression analysis to identify factors associated with partial mucosal recovery (MR) after GFD. We included in the multivariate analysis parameters available at the time of CD diagnosis.
Results: A total of 102 patients were enrolled, two thirds were females, median age of 39 years (yrs). The initial biopsy analysis showed different stages of villous atrophy (VA) in 79 (77.4%) cases, while in 23(22.5%) cases showed mild enteropathy (Marsh 1, 2). After at least 12 months of GFD, 26 (25.5%) patients had persistent VA despite good or excellent adherence to GFD. Younger patients (< 35yrs), who showed severe mucosal damage (Marsh 3c lesions) and who had increased anti-gliadin antibody (AGA) levels were at risk for failure to obtain mucosal recovery (MR). Logistic regression analysis demonstrated that complete mucosal atrophy (P=0.007) and high AGA antibody levels (cutoff 129 U/ml, P=0.001) were independent risk factors for lack of mucosal improvement after at least 12 months of GFD. Interestingly, genotype, tTG-IgA antibody levels, or duration of GFD levels did not influence the occurrence of MR.
Conclusion: Although AGA seropositivity has lost much of their diagnostic significance in recent years due to the introduction of the more sensitive and specific antibody tests, our study reported that patients aged < 35yrs, who showed severe mucosal damage (Marsh 3c lesions) and who had increased AGA antibody levels at diagnosis were at risk for failure to obtain MR. The elevated AGA levels at diagnosis could be used as a prognostic tool for assessing MR.
- celiac disease, gluten free diet, tissue transglutaminase, mucosal recovery, mucosal healing.
How to Cite
References
Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, et al. Celiac disease: a comprehensive current review. BMC Med 2019;17:142-148.
Maglio M, Troncone R. Intestinal anti-tissue transglutaminase2 autoantibodies: pathogenic and clinical implications for celiac disease. Front Nutr 2020;7:73.
Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J 2019;7:583-613.
Leonard MM, Weir DC, DeGroote M, Mitchell PD, Singh P, Silvester JA, et al. Value of IgA tTG in predicting mucosal recovery in children with celiac disease on a gluten-free diet. J Pediatr Gastroenterol Nutr 2017;64:286-291.
Murray JA, Rubio-Tapia A, Van Dyke CT, Brogan DL, Knipschield MA, Lahr B, et al. Mucosal atrophy in celiac disease: extent of involvement, correlation with clinical presentation, and response to treatment. Clin Gastroenterol Hepatol 2008;6:186-193.
Mandile R, Maglio M, Mosca C, Marano A, Discepolo V, Troncone R, et al. Mucosal healing in celiac disease: villous architecture and immunohistochemical features in children on a long-term gluten free diet. Nutrients 2022;14:3696.
Rubio-Tapia A, Rahim MW, See JA, Lahr BD, Wu TT, Murray JA. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010;105:1412-1420.
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997;3:797-801.
Kaur N, Minz RW, Bhadada SK, Saikia B, Dayal D, Anand S, et al. Role of anti-tissue transglutaminase IgA+IgG antibodies in detection of potential celiac disease in patients with type 1 diabetes. Indian J Med Res 2019;149:18-25.
Fang H, King KS, Larson JJ, Snyder MR, Wu TT, Gandhi MJ, et al. Undetectable negative tissue transglutaminase IgA antibodies predict mucosal healing in treated coeliac disease patients. Aliment Pharmacol Ther 2017;46:681-687.
Tye-Din JA. Editorial: a novel approach to monitor mucosal healing in coeliac disease-as simple as shifting goalposts? Aliment Pharmacol Ther 2017;46:894-895.
Marsh MN. Grains of truth: evolutionary changes in small intestinal mucosa in response to environmental antigen challenge. Gut 1990;31:111-114.
Hære P, Høie O, Schulz T, Schönhardt I, Raki M, Lundin KE. Long-term mucosal recovery and healing in celiac disease is the rule - not the exception. Scand J Gastroenterol 2016;51:1439-1446.
Leffler DA, Dennis M, Edwards George JB, Jamma S, Magge S, Cook EF, et al. A simple validated gluten-free diet adherence survey for adults with celiac disease. Clin Gastroenterol Hepatol 2009;7:530-536.
Ensari A, Marsh MN. Diagnosing celiac disease: a critical overview. Turk J Gastroenterol 2019;30:389-397.
Porcelli B, Ferretti F, Vindigni C, Terzuoli L. Assessment of a test for the screening and diagnosis of celiac disease. J Clin Lab Anal 2016;30:65-70.
Husby S, Murray JA, Katzka DA. AGA clinical practice update on diagnosis and monitoring of celiac disease-changing utility of serology and histologic measures: expert review. Gastroenterology 2019;156:885-889.
Lebwohl B, Granath F, Ekbom A, Montgomery SM, Murray JA, Rubio-Tapia A, et al. Mucosal healing and mortality in coeliac disease. Aliment Pharmacol Ther 2013;37:332-339.
Szakács Z, Mátrai P, Hegyi P, Szabó I, Vincze Á, Balaskó M, et al. Younger age at diagnosis predisposes to mucosal recovery in celiac disease on a gluten-free diet: a meta-analysis. PLoS One 2017;12:0187526.
Singh P, Lauwers GY, Garber JJ. Outcomes of seropositive patients with Marsh 1 histology in clinical practice. J Clin Gastroenterol 2016;50:619-623.
Sansotta N, Alessio MG, Norsa L, Previtali G, Ferrari A, Guerra G, et al. Trend of antitissue transglutaminase antibody normalization in children with celiac disease started on Gluten-free Diet: a comparative study between chemiluminescence and ELISA serum assays. J Pediatr Gastroenterol Nutr 2020;70:37–41.
Sheppard AL, Elwenspoek MMC, Scott LJ, Corfield V, Everitt H, Gillett PM, et al. Systematic review with meta-analysis: the accuracy of serological tests to support the diagnosis of coeliac disease. Aliment Pharmacol Ther 2022;55:514-527.
Adriaanse M, Leffler DA. Serum markers in the clinical management of celiac disease. Dig Dis 2015;33:236-243.
Raiteri A, Granito A, Giamperoli A, Catenaro T, Negrini G, Tovoli F. Current guidelines for the management of celiac disease: a systematic review with comparative analysis. World J Gastroenterol 2022;28:154-175.
Ziv-Baran T, Dubov Y, Weinberger R, Guz-Mark A, Shamir R, Assa A. Anti-tissue transglutaminase titers are associated with endoscopic findings and severity of mucosal damage in children with celiac disease. Eur J Pediatr 2021;180:263-269.
Galli G, Esposito G, Lahner E, Pilozzi E, Corleto VD, Di Giulio E, et al. Histological recovery and gluten-free diet adherence: a prospective 1-year follow-up study of adult patients with coeliac disease. Aliment Pharmacol Ther 2014;40:639-647.
Moreno ML, Rodríguez-Herrera A, Sousa C, Comino I. Biomarkers to monitor gluten-free diet compliance in celiac patients. Nutrients 2017;9:46.
Spatola BN, Kaukinen K, Collin P, Mäki M, Kagnoff MF, Daugherty PS. Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease. Aliment Pharmacol Ther 2014;39:407-417.
Wieser H, Ruiz-Carnicer Á, Segura V, Comino I, Sousa C. Challenges of monitoring the gluten-free diet adherence in the management and follow-up of patients with celiac disease. Nutrients 2021;13:2274.
Tye-Din JA. Review article: follow-up of coeliac disease. Aliment Pharmacol Ther 2022;56:49-63.
Vécsei E, Steinwendner S, Kogler H, Innerhofer A, Hammer K, Haas OA, et al. Follow-up of pediatric celiac disease: value of antibodies in predicting mucosal healing, a prospective cohort study. BMC Gastroenterol 2014;14:28.
Paolini A, Sarshar M, Felli C, Bruno SP, Rostami-Nejad M, Ferretti F, et al. Biomarkers to monitor adherence to gluten-free diet by celiac disease patients: gluten immunogenic peptides and urinary miRNAs. Foods 2022;11:1380.
Ciacci C, Gagliardi M, Siniscalchi M, Ruotolo M, Santonicola A, Hajji N, et al. Gluten Immunogenic Peptides (GIP) point-of-care urine test in coeliac disease follow-up before and during the COVID-19 lockdown in Italy. Clin Exp Gastroenterol 2021;14:451-456.
Nemteanu R, Ciortescu I, Hincu CE, Clim A, Gheorghe L, Trifan A, et al. Replacing the burden of the gluten free diet: then, now, and the future. Int J Mol Sci 2022;23:15108.
- Abstract Viewed: 78 times
- PDF Downloaded: 112 times